A Win For Monopar Therapeutics Inc.

Monopar Therapeutics Inc. (MNPR:NASDAQ) soared at $0.67, a gain of 96.6%. On Tue, Feb 20, 2024, MNPR:NASDAQ touched a New 2-Week High of $0.67. The stock appeared on our News Catalysts scanner on Tue, Feb 20, 2024 at 10:10 AM in the 'BIOTECH' category. From Tue, Feb 06, 2024, the stock recorded 44.44% Up Days and 10.00% Green Days

The stock spiked on Tue, Feb 20, 2024 at $1.56 with a volume of 100M+.

About Monopar Therapeutics Inc. (MNPR:NASDAQ)

Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.